Gilead, Galapagos finalise £4.1bn research and development deal

Gilead, Galapagos finalise £4.1bn research and development deal

Source: 
Pharmaceutical Business Review
snippet: 


Gilead Sciences has finalised its 10-year global research and development deal, worth up to $5.05bn (£4.11bn), with Belgium-based Galapagos following regulatory clearances.